[{"indications": "Indications\u00a0see under Dose and under Patches; opioid dependence (section 4.10.3)", "name": "BUPRENORPHINE - OPIOID ANALGESICS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "BUPRENORPHINE"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nCautions\u00a0Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).Palliative care\u00a0In the control of pain in terminal illness, the cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.; also impaired consciousness; effects only partially\r\nreversed by naloxone; monitor liver functionFever or external heat\u00a0Monitor patients\r\nusing patches for increased side-effects if fever present (increased\r\nabsorption possible); avoid exposing application\r\nsite to external heat (may also increase absorption)", "side-effects": "Side-effects\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nSide-effects\u00a0Opioid analgesics share many side-effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizziness, confusion, drowsiness, sleep disturbances, headache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual disturbances, sweating, flushing, rash, urticaria, and pruritus. Overdosage: see Emergency Treatment of Poisoning.Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.; can induce\r\nmild withdrawal symptoms in patients dependent on opioids; also diarrhoea,\r\nabdominal pain, anorexia, dyspepsia; vasodilatation; dyspnoea; paraesthesia,\r\nasthenia, fatigue, agitation, anxiety; less commonly flatulence, taste disturbance, angina, hypertension, syncope, hypoxia,\r\nwheezing, cough, restlessness, depersonalisation, dysarthria, impaired\r\nmemory, hypoaesthesia, tremor, influenza-like symptoms, pyrexia, rhinitis,\r\nrigors, muscle cramp, myalgia, tinnitus, dry eye, and dry skin; rarely paralytic ileus, dysphagia, impaired concentration,\r\nand psychosis; very rarely retching, hyperventilation,\r\nhiccups, and muscle fasciculation; hepatic necrosis and hepatitis\r\nalso reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3513.htm", "doses": ["Moderate to severe pain, by sublingual administration, 200\u2013400\u00a0micrograms every 6\u20138 hours; child over 6 years, 16\u201325\u00a0kg, 100\u00a0micrograms every 6\u20138 hours; 25\u201337.5\u00a0kg,\r\n100\u2013200\u00a0micrograms every 6\u20138 hours; 37.5\u201350\u00a0kg, 200\u2013300\u00a0micrograms\r\nevery 6\u20138 hours", "By intramuscular or slow\r\nintravenous injection, 300\u2013600\u00a0micrograms every 6\u20138 hours; child over 6 months 3\u20136\u00a0micrograms/kg every 6\u20138 hours\r\n(max. 9\u00a0micrograms/kg)", "Premedication, by sublingual administration, 400\u00a0micrograms", "By intramuscular injection, 300\u00a0micrograms", "Intra-operative analgesia, by slow intravenous injection, 300\u2013450\u00a0micrograms"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour. and %s\n(From Opioid substitution therapy: British National Formulary)\nPregnancy\u00a0Acute withdrawal of opioids should be avoided in pregnancy because it can cause fetal death. Opioid substitution therapy is recommended during pregnancy because it carries a lower risk to the fetus than continued use of illicit drugs. If a woman who is stabilised on methadone or buprenorphine for treatment of opioid dependence becomes pregnant, therapy should be continued [buprenorphine is not licensed for use in pregnancy]. Many pregnant patients choose a withdrawal regimen, but withdrawal during the first trimester should be avoided because it is associated with an increased risk of spontaneous miscarriage. Withdrawal of methadone or buprenorphine should be undertaken gradually during the second trimester; for example, the dose of methadone may be reduced by 2\u20133\u00a0mg every 3\u20135 days. If illicit drug use occurs, the patient should be re-stabilised at the optimal maintenance dose and consideration should be given to stopping the withdrawal regimen.Further withdrawal of methadone or buprenorphine in the third trimester is not recommended because maternal withdrawal, even if mild, is associated with fetal distress, stillbirth, and the risk of neonatal mortality. Drug metabolism can be increased in the third trimester; it may be necessary to either increase the dose of methadone or change to twice-daily consumption (or a combination of both strategies) to prevent withdrawal symptoms from developing.The neonate should be monitored for respiratory depression and signs of withdrawal if the mother is prescribed high doses of opioid substitute.Signs of neonatal withdrawal from opioids usually develop 24\u201372 hours after delivery but symptoms may be delayed for up to 14 days, so monitoring may be required for several weeks. Symptoms include a high-pitched cry, rapid breathing, hungry but ineffective suckling, and excessive wakefulness; severe, but rare symptoms include hypertonicity and convulsions."}, {"indications": "Indications\u00a0see under Dose and under Patches; opioid dependence (section 4.10.3)", "name": "BUPRENORPHINE Patches", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "BUPRENORPHINE", "Patches"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nCautions\u00a0Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).Palliative care\u00a0In the control of pain in terminal illness, the cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.; also impaired consciousness; effects only partially\r\nreversed by naloxone; monitor liver functionFever or external heat\u00a0Monitor patients\r\nusing patches for increased side-effects if fever present (increased\r\nabsorption possible); avoid exposing application\r\nsite to external heat (may also increase absorption)", "side-effects": "Side-effects\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nSide-effects\u00a0Opioid analgesics share many side-effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizziness, confusion, drowsiness, sleep disturbances, headache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual disturbances, sweating, flushing, rash, urticaria, and pruritus. Overdosage: see Emergency Treatment of Poisoning.Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.; can induce\r\nmild withdrawal symptoms in patients dependent on opioids; also diarrhoea,\r\nabdominal pain, anorexia, dyspepsia; vasodilatation; dyspnoea; paraesthesia,\r\nasthenia, fatigue, agitation, anxiety; less commonly flatulence, taste disturbance, angina, hypertension, syncope, hypoxia,\r\nwheezing, cough, restlessness, depersonalisation, dysarthria, impaired\r\nmemory, hypoaesthesia, tremor, influenza-like symptoms, pyrexia, rhinitis,\r\nrigors, muscle cramp, myalgia, tinnitus, dry eye, and dry skin; rarely paralytic ileus, dysphagia, impaired concentration,\r\nand psychosis; very rarely retching, hyperventilation,\r\nhiccups, and muscle fasciculation; hepatic necrosis and hepatitis\r\nalso reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106521.htm", "doses": ["Moderate to severe pain, by sublingual administration, 200\u2013400\u00a0micrograms every 6\u20138 hours; child over 6 years, 16\u201325\u00a0kg, 100\u00a0micrograms every 6\u20138 hours; 25\u201337.5\u00a0kg,\r\n100\u2013200\u00a0micrograms every 6\u20138 hours; 37.5\u201350\u00a0kg, 200\u2013300\u00a0micrograms\r\nevery 6\u20138 hours", "By intramuscular or slow\r\nintravenous injection, 300\u2013600\u00a0micrograms every 6\u20138 hours; child over 6 months 3\u20136\u00a0micrograms/kg every 6\u20138 hours\r\n(max. 9\u00a0micrograms/kg)", "Premedication, by sublingual administration, 400\u00a0micrograms", "By intramuscular injection, 300\u00a0micrograms", "Intra-operative analgesia, by slow intravenous injection, 300\u2013450\u00a0micrograms", "Name[Transtec\u00ae (Napp) ] Patches, self-adhesive, skin-coloured, buprenorphine, \u201835\u2019 patch (releasing 35\u00a0micrograms/hour\r\nfor 96 hours), net price 4 = \u00a315.73; \u201852.5\u2019 patch (releasing 52.5\u00a0micrograms/hour\r\nfor 96 hours), 4 = \u00a323.61; \u201870\u2019 patch (releasing 70\u00a0micrograms/hour\r\nfor 96 hours), 4 = \u00a331.46. \r\n    Label:\r\n    2Dose\u00a0moderate to severe chronic cancer pain and severe pain\r\nunresponsive to non-opioid analgesics, adult over 18 years, apply to dry, non-irritated, non-hairy skin on upper\r\ntorso, removing after no longer than 96 hours and siting replacement\r\npatch on a different area (avoid same area for at least 6 days). Patients\r\nwho have not previously received strong opioid analgesic, initially,\r\none \u201835\u00a0micrograms/hour\u2019 patch replaced after no longer than 96 hours;\r\npatients who have received strong opioid analgesic, initial dose based\r\non previous 24-hour opioid requirement, consult product literature Dose adjustment\u00a0When starting, analgesic effect\r\nshould not be evaluated until the system has been\r\nworn for 24 hours (to allow for gradual increase\r\nin plasma-buprenorphine concentration)\u2014if necessary, dose should be\r\nadjusted at intervals of no longer than 96 hours using a patch of\r\nthe next strength or using 2 patches of the same\r\nstrength (applied at same time to avoid confusion).\r\nMax. 2 patches can be used at any one time. For breakthrough pain,\r\nconsider 200\u2013400\u00a0micrograms buprenorphine sublingually. Important: it may take approx. 30 hours for the plasma-buprenorphine concentration\r\nto decrease by 50% after patch is removedLong duration of action\u00a0In view of the long duration\r\nof action, patients who have severe side-effects should be monitored\r\nfor up to 30 hours after removing patch"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour. and %s\n(From Opioid substitution therapy: British National Formulary)\nPregnancy\u00a0Acute withdrawal of opioids should be avoided in pregnancy because it can cause fetal death. Opioid substitution therapy is recommended during pregnancy because it carries a lower risk to the fetus than continued use of illicit drugs. If a woman who is stabilised on methadone or buprenorphine for treatment of opioid dependence becomes pregnant, therapy should be continued [buprenorphine is not licensed for use in pregnancy]. Many pregnant patients choose a withdrawal regimen, but withdrawal during the first trimester should be avoided because it is associated with an increased risk of spontaneous miscarriage. Withdrawal of methadone or buprenorphine should be undertaken gradually during the second trimester; for example, the dose of methadone may be reduced by 2\u20133\u00a0mg every 3\u20135 days. If illicit drug use occurs, the patient should be re-stabilised at the optimal maintenance dose and consideration should be given to stopping the withdrawal regimen.Further withdrawal of methadone or buprenorphine in the third trimester is not recommended because maternal withdrawal, even if mild, is associated with fetal distress, stillbirth, and the risk of neonatal mortality. Drug metabolism can be increased in the third trimester; it may be necessary to either increase the dose of methadone or change to twice-daily consumption (or a combination of both strategies) to prevent withdrawal symptoms from developing.The neonate should be monitored for respiratory depression and signs of withdrawal if the mother is prescribed high doses of opioid substitute.Signs of neonatal withdrawal from opioids usually develop 24\u201372 hours after delivery but symptoms may be delayed for up to 14 days, so monitoring may be required for several weeks. Symptoms include a high-pitched cry, rapid breathing, hungry but ineffective suckling, and excessive wakefulness; severe, but rare symptoms include hypertonicity and convulsions."}, {"indications": "Indications\u00a0adjunct in the treatment of opioid dependence;\r\npremedication, peri-operative analgesia, analgesia in other situations\r\n(section 4.7.2)", "name": "BUPRENORPHINE - OPIOID SUBSTITUTION THERAPY", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.10 Drugs used in substance dependence", "4.10.3 Opioid dependence", "Opioid substitution therapy", "BUPRENORPHINE"], "cautions": "Cautions\u00a0see Buprenorphine in section 4.7.2 and notes above; caution if pre-existing\r\nliver enzyme abnormalities, hepatitis B or C infection,\r\nor concomitant use of hepatotoxic drugs", "side-effects": "Side-effects\u00a0see Buprenorphine, section 4.7.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201580.htm", "doses": ["By sublingual administration, adult and child over\r\n16 years, initially, 0.8\u20134\u00a0mg on day 1, adjusted if necessary by 2\u20134\u00a0mg\r\ndaily to usual dose of 12\u201324\u00a0mg daily (max. 32\u00a0mg daily); withdraw\r\ngradually"], "pregnancy": "Pregnancy\u00a0\n(From Opioid substitution therapy: British National Formulary)\nPregnancy\u00a0Acute withdrawal of opioids should be avoided in pregnancy because it can cause fetal death. Opioid substitution therapy is recommended during pregnancy because it carries a lower risk to the fetus than continued use of illicit drugs. If a woman who is stabilised on methadone or buprenorphine for treatment of opioid dependence becomes pregnant, therapy should be continued [buprenorphine is not licensed for use in pregnancy]. Many pregnant patients choose a withdrawal regimen, but withdrawal during the first trimester should be avoided because it is associated with an increased risk of spontaneous miscarriage. Withdrawal of methadone or buprenorphine should be undertaken gradually during the second trimester; for example, the dose of methadone may be reduced by 2\u20133\u00a0mg every 3\u20135 days. If illicit drug use occurs, the patient should be re-stabilised at the optimal maintenance dose and consideration should be given to stopping the withdrawal regimen.Further withdrawal of methadone or buprenorphine in the third trimester is not recommended because maternal withdrawal, even if mild, is associated with fetal distress, stillbirth, and the risk of neonatal mortality. Drug metabolism can be increased in the third trimester; it may be necessary to either increase the dose of methadone or change to twice-daily consumption (or a combination of both strategies) to prevent withdrawal symptoms from developing.The neonate should be monitored for respiratory depression and signs of withdrawal if the mother is prescribed high doses of opioid substitute.Signs of neonatal withdrawal from opioids usually develop 24\u201372 hours after delivery but symptoms may be delayed for up to 14 days, so monitoring may be required for several weeks. Symptoms include a high-pitched cry, rapid breathing, hungry but ineffective suckling, and excessive wakefulness; severe, but rare symptoms include hypertonicity and convulsions."}, {"indications": "Indications\u00a0see under Dose and under Patches; opioid dependence (section 4.10.3)", "name": "BUPRENORPHINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "BUPRENORPHINE"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nCautions\u00a0Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).Palliative care\u00a0In the control of pain in terminal illness, the cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.; also impaired consciousness; effects only partially\r\nreversed by naloxone; monitor liver functionFever or external heat\u00a0Monitor patients\r\nusing patches for increased side-effects if fever present (increased\r\nabsorption possible); avoid exposing application\r\nsite to external heat (may also increase absorption)", "side-effects": "Side-effects\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nSide-effects\u00a0Opioid analgesics share many side-effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizziness, confusion, drowsiness, sleep disturbances, headache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual disturbances, sweating, flushing, rash, urticaria, and pruritus. Overdosage: see Emergency Treatment of Poisoning.Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.; can induce\r\nmild withdrawal symptoms in patients dependent on opioids; also diarrhoea,\r\nabdominal pain, anorexia, dyspepsia; vasodilatation; dyspnoea; paraesthesia,\r\nasthenia, fatigue, agitation, anxiety; less commonly flatulence, taste disturbance, angina, hypertension, syncope, hypoxia,\r\nwheezing, cough, restlessness, depersonalisation, dysarthria, impaired\r\nmemory, hypoaesthesia, tremor, influenza-like symptoms, pyrexia, rhinitis,\r\nrigors, muscle cramp, myalgia, tinnitus, dry eye, and dry skin; rarely paralytic ileus, dysphagia, impaired concentration,\r\nand psychosis; very rarely retching, hyperventilation,\r\nhiccups, and muscle fasciculation; hepatic necrosis and hepatitis\r\nalso reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3513.htm", "doses": ["Moderate to severe pain, by sublingual administration, 200\u2013400\u00a0micrograms every 6\u20138 hours; child over 6 years, 16\u201325\u00a0kg, 100\u00a0micrograms every 6\u20138 hours; 25\u201337.5\u00a0kg,\r\n100\u2013200\u00a0micrograms every 6\u20138 hours; 37.5\u201350\u00a0kg, 200\u2013300\u00a0micrograms\r\nevery 6\u20138 hours", "By intramuscular or slow\r\nintravenous injection, 300\u2013600\u00a0micrograms every 6\u20138 hours; child over 6 months 3\u20136\u00a0micrograms/kg every 6\u20138 hours\r\n(max. 9\u00a0micrograms/kg)", "Premedication, by sublingual administration, 400\u00a0micrograms", "By intramuscular injection, 300\u00a0micrograms", "Intra-operative analgesia, by slow intravenous injection, 300\u2013450\u00a0micrograms"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour. and %s\n(From Opioid substitution therapy: British National Formulary)\nPregnancy\u00a0Acute withdrawal of opioids should be avoided in pregnancy because it can cause fetal death. Opioid substitution therapy is recommended during pregnancy because it carries a lower risk to the fetus than continued use of illicit drugs. If a woman who is stabilised on methadone or buprenorphine for treatment of opioid dependence becomes pregnant, therapy should be continued [buprenorphine is not licensed for use in pregnancy]. Many pregnant patients choose a withdrawal regimen, but withdrawal during the first trimester should be avoided because it is associated with an increased risk of spontaneous miscarriage. Withdrawal of methadone or buprenorphine should be undertaken gradually during the second trimester; for example, the dose of methadone may be reduced by 2\u20133\u00a0mg every 3\u20135 days. If illicit drug use occurs, the patient should be re-stabilised at the optimal maintenance dose and consideration should be given to stopping the withdrawal regimen.Further withdrawal of methadone or buprenorphine in the third trimester is not recommended because maternal withdrawal, even if mild, is associated with fetal distress, stillbirth, and the risk of neonatal mortality. Drug metabolism can be increased in the third trimester; it may be necessary to either increase the dose of methadone or change to twice-daily consumption (or a combination of both strategies) to prevent withdrawal symptoms from developing.The neonate should be monitored for respiratory depression and signs of withdrawal if the mother is prescribed high doses of opioid substitute.Signs of neonatal withdrawal from opioids usually develop 24\u201372 hours after delivery but symptoms may be delayed for up to 14 days, so monitoring may be required for several weeks. Symptoms include a high-pitched cry, rapid breathing, hungry but ineffective suckling, and excessive wakefulness; severe, but rare symptoms include hypertonicity and convulsions."}, {"indications": "Indications\u00a0adjunct in the treatment of opioid\r\ndependence", "name": "BUPRENORPHINE WITH NALOXONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.10 Drugs used in substance dependence", "4.10.3 Opioid dependence", "Opioid substitution therapy", "BUPRENORPHINE WITH NALOXONE"], "cautions": "Cautions\u00a0see Buprenorphine", "side-effects": "Side-effects\u00a0see under Buprenorphine in section 4.7.2 and Naloxone in section 15.1.7; also weight loss, arthralgia; less commonly yawning, heat stroke, hypothermia, vaginitis,\r\nanaemia, thrombocytopenia, leucopenia, lymphadenopathy, leucocytosis,\r\nhaematuria, urinary calculus, conjunctivitis, exfoliative dermatitis,\r\nacne, skin nodule, alopecia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/213816.htm", "doses": ["See under preparation", "expressed as buprenorphine, adult and child over 15 years, initially\r\n2\u20134\u00a0mg once daily (an additional dose of 2\u20134\u00a0mg may be administered\r\non day 1 depending on the individual patient\u2019s requirement), increased\r\nin steps of 2\u20138\u00a0mg according to response; max. 24\u00a0mg daily; total\r\nweekly dose may be divided and given on alternate days or 3 times\r\nweekly (but max. 24\u00a0mg daily)", "The Scottish Medicines\r\nConsortium has advised (February 2007) that Suboxone\u00ae should be restricted for use in patients in whom\r\nmethadone is not suitable"], "pregnancy": "Pregnancy\u00a0reproductive toxicity in animal studies\u2014switch\r\nto buprenorphine; see also notes above"}]